Multiple Myeloma Expert Roundtable: Stem Cell Transplantation, Maintenance Therapy, and Relapsed/Refractory Disease
Jointly provided by
Support for this activity has been provided through educational grants from Amgen, Celgene Corporation, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Scroll to the Bottom of this Information to Begin this Course
Release date: December 27, 2017
Valid through: December 27, 2018
Specialty: Hematology/Oncology, Oncology
Topic: Multiple Myeloma
Estimated Time to Complete Activity: 60 minutes
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma.
With numerous recent advances in available treatments and options for diagnosis and staging, disease monitoring, and supportive care, the outlook for patients with multiple myeloma has never been brighter. However, this expansion of clinical options has also introduced potentially daunting challenges for the health care providers charged with the care of these patients.
This activity presents a robust roundtable discussion in which our expert faculty provides insights on such issues as determining the optimal timing and approach for autologous stem cell transplantation (ASCT), considering new factors when weighing the benefits and risks of maintenance therapy, and choosing between the various therapeutic options in the relapsed/refractory setting. This activity includes downloadable resources (including supplemental figures and tables).
Upon completion of this activity, participants should be better able to:
- Evaluate emerging data regarding the optimal timing and approach to ASCT
- Identify patients who would benefit from maintenance therapy
- Incorporate the use of novel agent/monoclonal antibody–based regimens for a relapsed or refractory patient based on currently available evidence
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other health care professionals completing this course will be issued a statement of participation.
Amrita Y. Krishnan, MD
Professor, Department of Hematology & Hematopoietic Cell Transplantation
Director, Judy and Bernard Briskin Center for Multiple Myeloma Research
City of Hope Medical Center
Amrita Y. Krishnan completed her medical degree at Albany Medical College in New York as part of a combined BS-MD six-year accelerated program, where she was selected for the Alpha Omega Alpha Honor Medical Society. Her postdoctoral training comprised residency and internship in the Strong Memorial Hospital Department of Medicine at the University of Rochester, as well as fellowships at City of Hope Medical Center, Harvard Medical School Beth Israel Hospital, and the Dana Farber Cancer Institute.
Dr. Krishnan is a Diplomate of the American Board of Oncology, the American Board of Hematology, and the American Board of Internal Medicine. She is also active in several professional societies. She is the former Chair of the American Society of Clinical Oncology plasma cell committee and past Co-Chair of the Center for International Blood and Marrow Transplant Research Plasma Cell Committee, and she currently serves as Chair of the Blood and Marrow Transplant Clinical Trials Network myeloma committee and subcommittee member of the American Society of Hematology, American Society for Blood and Marrow Transplantation, and the Multiple Myeloma Research Consortium.
Dr. Krishnan has authored almost 200 articles, abstracts, and book chapters, and she is a reviewer for several journals, including American Journal of Hematology, Bone Marrow Transplantation, Haematologica, Blood, and Biology of Blood and Marrow Transplantation. An active researcher, Dr. Krishnan was instrumental in bringing successful transplant therapy to HIV patients with lymphoma, when many believed such patients were too weak to tolerate the procedure. She is currently the principal investigator of an innovative trial utilizing zinc finger nuclease–based stem cell therapy for HIV treatment. She is also the co-chair of one of the largest myeloma transplant trials in the United States evaluating the role of the best post transplant therapy in the era of modern myeloma agents.
Gareth J. Morgan, MD, PhD
Professor of Medicine
Director, Myeloma Institute
Deputy Director, Winthrop P. Rockefeller Cancer Institute
University of Arkansas for Medical Sciences Myeloma Institute
Little Rock, Arkansas
Gareth J. Morgan received his doctorate on the genetics of leukemia from the University of London in 1991 and his bachelor of medicine in 1981 from the Welsh National School of Medicine. His postgraduate medical training was completed in Wales and at the Royal Postgraduate Medical School in London. He joined the University of Arkansas for Medical Sciences (UAMS) Myeloma Institute as director of its myeloma program in 2013. Prior to joining the UAMS faculty, Dr. Morgan was at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research in London, for which he served as Professor of Haematology and Director of the Centre for Myeloma Research.
An internationally recognized clinician scientist specializing in the molecular genetics of blood cell cancers (in particular, multiple myeloma), Dr. Morgan is specifically interested in how this knowledge can improve the treatment of cancer. He is doing influential work on the characterization of the myeloma genome, defining specific subsets of the disease that have prognostic importance and developing personalized therapeutic strategies targeted to each subtype. He is also engaged in advanced research in molecular diagnostics, drug development, and clinical trials. His research aims to cure myeloma and to reduce side effects by targeting treatment to the biology underlying each patient’s cancer.
Dr. Morgan has published extensively in the peer-reviewed literature, he serves as a reviewer for several journals, and he has authored and edited a number of books and book chapters. He is a frequent invited speaker.
Saad Z. Usmani, MD, FACP
Director, Plasma Cell Disorders Program
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina
Saad Zafar Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr. Usmani joined the faculty of the Levine Cancer Institute in July 2013; he also currently holds an academic appointment as Clinical Professor of Medicine at the University of North Carolina-Chapel Hill School of Medicine. Previously, Dr. Usmani served as an Assistant Professor of Medicine at the University of Arkansas for Medical Sciences in Little Rock, Arkansas and Director of Developmental Therapeutics at the Myeloma Institute for Research & Therapy.
Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and he is a Fellow of the American College of Physicians. He holds membership in several professional societies, including the International Myeloma Working Group, the SWOG Myeloma Committee, the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the American Society of Bone Marrow Transplantation. Dr. Usmani currently serves as the Track Leader on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, and he is a member of the ASH Committee on Plasma Cell Neoplasia and the National Cancer Institute Myeloma Steering Committee. Among his many honors, Dr. Usmani received the Lasco Cancer Fund Carolyn Wilson Courage Award in 2015. Additionally, he was the Session Chair for the ASCO Annual Meetings in 2013 and 2015.
Active in clinical and translational research, Dr. Usmani has served as a principal investigator for more than 35 clinical trials (phase 1–3). His research interests focus on plasma cell disorders—in particular, high-risk multiple myeloma. He is a specialist in hematology, medical oncology, and bone marrow transplantation and has authored or co-authored more than 70 peer-reviewed research manuscripts and more than 90 abstracts at national and international meetings. He is also on the editorial review board of numerous medical journals.
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine (PSCM), RedMedEd, and the Multiple Myeloma Research Foundation (MMRF). PSCM is accredited by the ACCME to provide continuing medical education for physicians.
PSCM designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
- Consultant/Advisor: Celgene, Janssen
- Speakers Bureau: Celgene, Janssen, Takeda
- Stock Ownership: Celgene, Kite
- Consultant/Advisor: Bristol-Myers Squibb, Celgene, Roche, Takeda Oncology
- Consultant/Advisor: Amgen, Celgene, Sanofi, Takeda
- Research Grant: Array, Bristol-Myers Squibb, Celgene, Janssen, Onyx Pharmaceuticals, Pharmacyclics, Sanofi
- Speakers Bureau: Bio Pharma, Celgene, Novartis, Onyx Pharmaceuticals, Sanofi, Takeda Oncology
- Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
- Mary DeRome, Director of Medical Communications and Education, has disclosed no relevant financial relationships.
- Denise C. LaTemple, PhD, Director of Scientific Services: no relevant financial relationships.
- Kristen Petro Slade, Director of Operations: no relevant financial relationships.
- Jonathan S. Simmons, ELS, Senior Managing Editor: no relevant financial relationships.
- Karen Smith, Creative Director: no relevant financial relationships.
- Karen Tenaglia, Project Manager: no relevant financial relationships.
Instructions for Participation and Credit
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6163-18-T.
Hardware and Software Requirements
This site is best viewed with an HTML5-compatible browser; this includes versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Safari. You can visit the independent (third party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. PSCM, RedMedEd, the MMRF, Amgen, Celgene Corporation, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PSCM, RedMedEd, the MMRF, Amgen, Celgene Corporation, or Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.